Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 17/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 17/20 | 0.55 |
| ▸ | PDE4C | Q08493 | 17/20 | 0.55 |
| ▸ | PDE4D | Q08499 | 17/20 | 0.55 |
| ▸ | PDE3B | Q13370 | 8/20 | 0.52 |
| ▸ | PDE3A | Q14432 | 8/20 | 0.52 |
| ▸ | USP1 | O94782 | 1/20 | 0.47 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.47 |
| ▸ | PDE5A | O76074 | 1/20 | 0.46 |
| ▸ | APP | P05067 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21567217 | 0.86 | PDE4A (0.69) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL23498518 | 0.85 | PDE4A (0.64) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL7070989 | 0.79 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL20399061 | 0.79 | MEN1 (0.49) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL30092963 | 0.79 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL21567304 | 0.79 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL20399014 | 0.77 | PDE4A (0.79) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL23498669 | 0.77 | ADORA2A (0.50) | PDE4APDE4BPDE4CPDE4DPDE3B | |
| SCHEMBL28354910 | 0.76 | LRRK2 (0.48) | — | |
| SCHEMBL20402660 | 0.76 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4DPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | INFECTIOUS DISEASE RESEARCH INSTITUTE (US) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317607-A1 | USE OF COMPOUNDS FOR PREPARING ANTI-TUBERCULOSIS AGENTS | TPX2, DCXR, RRM2 | PDE4A 1342/4885PDE4B 681/4885PDE4C 1416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.